Enzolytics and BioClonetics intent to merge sends stock parabolic
Enzolytics, Inc, a drug development company with a focus on debilitating infectious diseases, announced on September 16, the execution of
Read moreEnzolytics, Inc, a drug development company with a focus on debilitating infectious diseases, announced on September 16, the execution of
Read moreBristol Myers Squibb is strengthening its cardiovascular pipeline through a $13.1 Billion acquisition of biotech firm MyoKardia. The $13.1 Billion
Read moreAstraZeneca’s FARXIGA® was granted Breakthrough Therapy Designation (BTD) in the U.S. for Chronic Kidney Disease, following the DAPA-CKD Phase III
Read moreAbbott, a global leader in continuous glucose monitoring (CGM) technology, announced it has been awarded CE Mark (Conformité Européenne) for
Read moreAbbott declared the first patient has been enrolled in the DISTINCT study (Dorsal spInal cord STImulatioN vs mediCal management for
Read moreJanssen’s Golimumab, a human monoclonal antibody used as an immunosuppressive drug and sold under the brand name Simponi, has received
Read moreNext-gen immunotherapy company BioNTech announced this month the completion of a share purchase agreement with Swiss pharma giant Novartis AG,
Read moreIrish biotechnology firm Inflazome announced today that it has closed a share purchase agreement with Swiss pharma giant Roche in
Read moreSwiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read moreDarmstadt headquartered Merck KGaA, a leading science and technology company operating in the U.S. & Canada as MilliporeSigma, has announced a
Read more